A detailed history of Royal Bank Of Canada transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 4,923 shares of DSGN stock, worth $29,390. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,923
Previous 2,953 66.71%
Holding current value
$29,390
Previous $9,000 188.89%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.19 - $5.88 $6,284 - $11,583
1,970 Added 66.71%
4,923 $26,000
Q2 2024

Aug 14, 2024

BUY
$3.23 - $4.77 $7,167 - $10,584
2,219 Added 302.32%
2,953 $9,000
Q1 2024

Nov 05, 2024

SELL
$2.27 - $4.03 $5,037 - $8,942
-2,219 Reduced 75.14%
734 $2,000
Q1 2024

May 15, 2024

SELL
$2.27 - $4.03 $22,847 - $40,561
-10,065 Reduced 93.2%
734 $2,000
Q4 2023

Feb 14, 2024

BUY
$1.99 - $2.76 $10,543 - $14,622
5,298 Added 96.31%
10,799 $28,000
Q3 2023

Nov 14, 2023

BUY
$2.05 - $8.14 $3,950 - $15,685
1,927 Added 53.92%
5,501 $12,000
Q2 2023

Aug 14, 2023

BUY
$4.99 - $7.64 $7,524 - $11,521
1,508 Added 72.99%
3,574 $22,000
Q1 2023

May 15, 2023

SELL
$5.5 - $9.77 $10,191 - $18,103
-1,853 Reduced 47.28%
2,066 $11,000
Q4 2022

Feb 14, 2023

BUY
$7.86 - $17.2 $27,549 - $60,286
3,505 Added 846.62%
3,919 $40,000
Q3 2022

Nov 14, 2022

BUY
$14.09 - $25.57 $3,156 - $5,727
224 Added 117.89%
414 $7,000
Q2 2022

Aug 15, 2022

SELL
$9.91 - $17.33 $14,310 - $25,024
-1,444 Reduced 88.37%
190 $3,000
Q1 2022

May 16, 2022

SELL
$11.17 - $20.89 $47,662 - $89,137
-4,267 Reduced 72.31%
1,634 $26,000
Q4 2021

Feb 14, 2022

BUY
$13.64 - $21.41 $58,802 - $92,298
4,311 Added 271.13%
5,901 $126,000
Q3 2021

Nov 15, 2021

BUY
$13.99 - $20.03 $9,345 - $13,380
668 Added 72.45%
1,590 $23,000
Q2 2021

Aug 16, 2021

BUY
$19.02 - $29.78 $17,536 - $27,457
922 New
922 $18,000

Others Institutions Holding DSGN

About Design Therapeutics, Inc.


  • Ticker DSGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,807,900
  • Market Cap $333M
  • Description
  • Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...
More about DSGN
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.